<DOC>
	<DOCNO>NCT02359162</DOCNO>
	<brief_summary>Purpose : To compare efficacy safety P-Gemox chemotherapy regimen EPOCH regimen stage IE IIE ENKTL .</brief_summary>
	<brief_title>Efficacy Safety Study P-Gemox vs.EPOCH First-line Chemotherapy Treat NK/T-cell Lymphoma With Early Stage</brief_title>
	<detailed_description>ENKTL aggressive type NHL characterize poor survival , optimal treatment strategy fully define . Radiation therapy ( RT ) widely administer patient localize nasal disease , produce complete response ( CR ) rate 70 % .However , local systemic failure observe frequently patient receive RT alone.Therefore , chemotherapy need combination RT reduce risk recurrence . Unfortunately , ENKTL show poor response CHOP chemotherapy regimen ( cyclophosphamide , doxorubicin , vincristine prednisone ) . EPOCH ( etoposide , vincristine , doxorubicin , cyclophosphamide prednisone ) chemotherapy follow involved field radiotherapy ( IFRT ) result CR rate 75.0 % . Recently , chemotherapy regimen include gemcitabine , oxaliplatin l-asparaginase ( GELOX ) emerge , promise results.Since 2003 , proportion patient newly diagnose ENKTL treat EPOCH chemotherapy regimen hospital China . From 2008 , many hospital southern part China begin use GELOX ( Pegaspargase use instead l-asparaginase , P-Gemox ) .Our multicenter retrospective study show GELOX regimen produce good long outcome less toxicity EPOCH regimen patient early stage ENKTL.However , prospective randomize clinical trial need confirm conclusion . 1 . Patients - All patient sign write informed consent form enrollment , study approve Sun Yat-sen University Cancer Center Ethics Board . - Baseline patient : Computed tomography ( CT ) scan chest , abdomen , pelvis , magnetic resonance image study head neck , bilateral bone marrow aspiration biopsy . Positron emission tomography-CT scan ( optional ) . Epstein-Barr virus ( E B V ) DNA blood level , titer EBV antibody ( EA-IgA , VCA-IgA ) , β2-micro globulin ( β2-MG ) , IL-9 IL-15 serum . - Recheck every course : Epstein-Barr virus ( EBV ) DNA blood level , titer EBV antibody ( EA-IgA , VCA-IgA ) , β2-micro globulin ( β2-MG ) , IL-9 IL-15 serum . - Recheck every two course : Computed tomography ( CT ) scan chest , abdomen , pelvis , magnetic resonance image study head neck , bilateral bone marrow aspiration biopsy . Positron emission tomography-CT scan ( optional ) 2 . Treatment Protocol : - The GELOX regimen consist follow drug : gemcitabine ：1250 mg/ m2 day 1 , ivdrip oxaliplatin ：85 mg/m2 day 1 , ivdrip pegaspargase : 2500 IU/m 2 daily day 1 , intramuscular . The treatment cycle repeat every 14 day . - The EPOCH regimen include 24 h continuous infusion etoposide ( 50 mg/m 2 /day ) , vincristine ( 0.4 mg/m 2 /day ) doxorubicin ( 10 mg/m 2 /day administer day 1-4 , follow cyclophosphamide ( 750 mg/m2 /day ) 15 min intravenously day 5 prednisone ( 60 mg/m 2 /day ) 60 mg/m 2 /day day 1-5.The treatment cycle repeat every 21 day . After least two cycle chemotherapy , patient achieve stable disease ( SD ) follow two cycle , partial response ( PR ) four cycle complete response ( CR ) six cycle chemotherapy refer primary IFRT . ◦IFRT deliver use 6-MeV linear accelerator use 3-dimensional conformable treatment planning . The IFRT dose 56 gray ( Gy ) 28 fraction , define clinical target volume limited stage IE disease bilateral nasal cavity , bilateral ethmoid sinus , ipsilateral maxillary sinus ; clinical target volume would extend involved tissue patient extensive stage IE disease . For patient stage IIE disease , clinical target volume also , include bilateral cervical lymph node area .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>newly diagnose ENKTL age:1869years Ann Arbor stage IE , stage IIE cervical lymph node involvement lease one measurable lesion receive chemotherapy radiotherapy Eastern CooperativeOncology Group performance status 0 2 . Adequate hematologic function ( eg , white blood cell ≥ 3×10e9/l , neutrophil count ≥1.5×10e9/L , platelet count≥ 100×10e9/L ) , renal function ( eg , serum creatinine≤1.5 mg/dL creatinine clearance ≥50 mL minute ) , hepatic function ( e.g , total bilirubin≤ 2 time upper limit normal aspartate alanine transaminase level ≤ 3 time upper limit normal ) mismatch inclusion criterion systematic central nervous system involvement , previous concomitant malignancy coexist medical problem could cause poor compliance study protocol . primary lesion upper respiratory</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NK/T-cell lymphoma</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>survival</keyword>
</DOC>